Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively.
By: Faith Ashmore Benzinga Staff Writer As of 2023,, the estimated number of Americans living with Alzheimer’s disease was 6.7 million. However, a lesser-known subsection of Alzheimer’s is Agitation in dementia
By: Faith Ashmore Benzinga Staff Writer Alzheimer’s disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact
On this day let’s talk about the power of education and how it can bring hope and understanding to patients, caregivers, and families affected by this condition.
This episode features an interview with Ram Mukunda and Claudia Grimaldi from IGC Pharma, a clinical-stage pharmaceutical company
Ram Mukunda and Claudia Grimaldi, representing IGC Pharma, a pharmaceutical company in the clinical stage dedicated to enhancing the health of Alzheimer’s disease patients and making these treatments accessible, appear on eHealth Radio and the Alzheimer’s Information and Health News Channels.
Kenia Andrade, Pharma Marketing Manager at IGC Pharma overseeing HOLIEF, a holistic women’s health brand from IGC Pharma and Dr. Juanita Arbelaez, Medical Researcher at IGC Pharma joins eHealth Radio and the Female Health and Health News Channels.
IGC will aim for FDA fast-track designation after a Phase II trial investigating IGC-AD1 with AD patients concludes in Q1 2024.
Discover cutting-edge dementia science at AAIC Amsterdam. Breakthroughs and connections thrive as leading experts unite at the world’s largest conference on Alzheimer’s research.
Discover the remarkable innovation of IGC Pharma, highlighted in BENZINGA publication.
Subscribe to get our latest content by email.
